Skip to main content

Orenstein Daniel H.'s Form 4 filing

Health Catalyst, Inc. (HCAT) · filed Dec 7, 2021

Accession no.
0001562180-21-007531
Filed
Dec 7, 2021
Trade date
Dec 2-6, 2021
Filing delay
5 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $284.8K. It was filed 5 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Orenstein Daniel H.CIK 0001494174Officer (General Counsel)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 2, 2021Common StockFTax withholdingDisposed−4,117$41.95F2−$172,708.1571,429Direct
Dec 3, 2021Common StockMOption exerciseAcquired+2,500$10.34+$25,85073,929Direct
Dec 3, 2021Common StockSSaleDisposed−2,500$42.87−$107,17571,429Direct
Dec 6, 2021Common StockSSaleDisposed−1,100$37.53F4−$41,28370,329Direct
Dec 6, 2021Common StockSSaleDisposed−3,533$38.60F5−$136,373.866,796Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 3, 2021Common StockMOption exerciseDisposed−2,500$0.00$0118,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents a weighted average price reported by the broker. These shares were sold as part of a block trade in multiple transactions at prices ranging from $40.33 to $42.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote with regard to the block trade.

Referenced by the price of 1 transaction in Table I.

F4

Represents the weighted average sale price of the shares sold ranging from $37.35 to $37.69 per share, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

Represents the weighted average sale price of the shares sold ranging from $38.35 to $39.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (4) and (5).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)